AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...
Emraclidine was the main reason AbbVie acquired Cerevel for $8.7 billion, and I expect a substantial impairment charge on ...
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
AbbVie raises profit forecast as CEO cites business "momentum" Digital ad sellers jump as Google, Reddit and Snap earnings indicate sturdy demand Illinois Tool Works earnings beat by $0.14 ...
AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...
AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...
It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, ...
which is $1.3 billion ahead of AbbVie’s initial expectations. Skyrizi’s impressive clinical results have allowed it to achieve in-play biologic share leadership in 30 key countries in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback